Johnson & Johnson (JNJ)
173.33
+1.80 (1.05%)
NYSE · Last Trade: Aug 9th, 1:34 AM EDT
Detailed Quote
Previous Close | 171.53 |
---|---|
Open | 171.02 |
Bid | 171.26 |
Ask | 173.80 |
Day's Range | 170.39 - 173.96 |
52 Week Range | 140.68 - 173.96 |
Volume | 7,686,826 |
Market Cap | 455.63B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (3.00%) |
1 Month Average Volume | 9,193,496 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.
Via Benzinga · August 8, 2025
Recent economic data from the United States has presented a nuanced picture of the nation's labor market, with a slight uptick in unemployment benefit applications alongside a significantly lower-than-expected nonfarm jobs report. While the increase in jobless claims remains within its recent range and is not immediately indicative of a
Via MarketMinute · August 7, 2025
The intricate dance between political shifts and financial markets has once again taken center stage, demonstrating the profound influence of electoral outcomes and subsequent policy decisions on global economies. The U.S. presidential election, a quadrennial event of immense significance, consistently introduces periods of heightened uncertainty and volatility, often culminating
Via MarketMinute · August 7, 2025
The United States economy is currently grappling with a complex and often contradictory narrative, marked by recent weak payrolls data, a discernible slowdown in the labor market, and persistent inflationary pressures. This confluence of factors is sending ripples through the stock market, prompting increased volatility and a significant re-evaluation of
Via MarketMinute · August 7, 2025
A troubling confluence of recent economic data points has sent a shiver through financial markets, reigniting fears of "stagflation"—a dreaded economic scenario characterized by stagnant growth, high unemployment, and persistent inflation. The flat reading in the ISM Services index for July, a significantly weaker-than-expected jobs report, and a narrowing
Via MarketMinute · August 6, 2025
The global financial markets are grappling with a growing sense of unease as recent economic data points to a troubling confluence of high inflation and sluggish growth, rekindling fears of stagflation. Weaker-than-expected figures from key indicators, including the ISM Services index, the latest jobs report, and the US trade deficit,
Via MarketMinute · August 6, 2025
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.
Via Benzinga · August 6, 2025
Major Wall Street firms, including Morgan Stanley (NYSE: MS), Deutsche Bank AG (NYSE: DB), and Evercore ISI (NYSE: EVR), have issued cautionary advisories to their clients, signaling a potential stock market pullback of 10-15% in the third quarter of 2025. These warnings come on the heels of a robust rally
Via MarketMinute · August 5, 2025
While monthly jobs reports often grab headlines, savvy investors are increasingly looking beyond employment figures to a broader array of economic indicators for a more nuanced understanding of market health. Two such crucial metrics, Personal Consumption Expenditures (PCE) inflation and the Chicago Purchasing Managers' Index (PMI), are currently providing critical
Via MarketMinute · August 5, 2025
Concerns are mounting among financial analysts that the U.S. stock market may be entering an "overheated" phase, with equity valuations reaching levels that some deem unsustainable. This apprehension comes as major indices continue to flirt with record highs, prompting a critical debate about the market's current trajectory and its
Via MarketMinute · August 5, 2025
Johnson & Johnson (JNJ) is a top dividend stock with a 3.16% yield, consistent growth, and strong profitability, making it ideal for income investors seeking stability.
Via Chartmill · August 5, 2025
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,
Via MarketMinute · August 4, 2025
Via Benzinga · August 3, 2025
Can the stock still deliver the same kinds of returns it has over the past few decades?
Via The Motley Fool · August 2, 2025
Via Benzinga · August 1, 2025
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinchstocktwits.com
Via Stocktwits · July 31, 2025
Microsoft and Meta Platforms added over $400 billion in market capitalization after reporting robust earnings results on Wednesday.
Via Benzinga · July 31, 2025
Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th, 2025. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · July 30, 2025
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, with more data expected.
Via Benzinga · July 29, 2025
The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.
Via Benzinga · July 29, 2025
These top Dow dividend stocks have long dividend growth streaks.
Via The Motley Fool · July 28, 2025
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.
Via The Motley Fool · July 28, 2025
Plan now for a rotation away from riskier and volatile technology growth stocks and toward blue chips with more promise and predictability.
Via The Motley Fool · July 27, 2025
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via Benzinga · July 26, 2025